These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 10912142

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
    Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, Joe A, Roedel R, Fimmers R, Knapp FF, Guhlke S, Biersack HJ.
    J Clin Oncol; 2003 Aug 01; 21(15):2869-75. PubMed ID: 12885803
    [Abstract] [Full Text] [Related]

  • 3. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.
    Maxon HR, Schroder LE, Hertzberg VS, Thomas SR, Englaro EE, Samaratunga R, Smith H, Moulton JS, Williams CC, Ehrhardt GJ.
    J Nucl Med; 1991 Oct 01; 32(10):1877-81. PubMed ID: 1717669
    [Abstract] [Full Text] [Related]

  • 4. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
    De Klerk JM, Zonnenberg BA, Blijham GH, Van Het Schip AD, Hoekstra A, Han SH, Quirijnen JM, Van Dijk A, Van Rijk PP.
    Anticancer Res; 1997 Oct 01; 17(3B):1773-7. PubMed ID: 9179233
    [Abstract] [Full Text] [Related]

  • 5. Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment.
    de Klerk JM, Zonnenberg BA, Krouwer HG, Blijham GH, van Dijk A, van het Schip AD, van Die J, van Rijk PP.
    J Nucl Med; 1996 Mar 01; 37(3):465-7. PubMed ID: 8772646
    [Abstract] [Full Text] [Related]

  • 6. 186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases.
    Han SH, De Klerk JM, Zonnenberg BA, Tan S, Van Rijk PP.
    Q J Nucl Med; 2001 Mar 01; 45(1):84-90. PubMed ID: 11456380
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
    Minutoli F, Herberg A, Spadaro P, Restifo Pecorella G, Baldari S, Aricò D, Altavilla G, Baldari S.
    Q J Nucl Med Mol Imaging; 2006 Dec 01; 50(4):355-62. PubMed ID: 17043634
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases.
    de Klerk JM, van Dijk A, van het Schip AD, Zonnenberg BA, van Rijk PP.
    J Nucl Med; 1992 May 01; 33(5):646-51. PubMed ID: 1373767
    [Abstract] [Full Text] [Related]

  • 10. Application of rhenium-188 HEDP in bone metastases therapy.
    Scheffler J, Derejko M, Bandurski T, Romanowicz G.
    Nucl Med Rev Cent East Eur; 2003 May 01; 6(1):55-7. PubMed ID: 14600935
    [Abstract] [Full Text] [Related]

  • 11. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.
    Han SH, de Klerk JM, Tan S, van het Schip AD, Derksen BH, van Dijk A, Kruitwagen CL, Blijham GH, van Rijk PP, Zonnenberg BA.
    J Nucl Med; 2002 Sep 01; 43(9):1150-6. PubMed ID: 12215552
    [Abstract] [Full Text] [Related]

  • 12. [Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases].
    Liepe K, Franke WG, Kropp J, Koch R, Runge R, Hliscs R.
    Nuklearmedizin; 2000 Sep 01; 39(6):146-51. PubMed ID: 11057405
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
    Kolesnikov-Gauthier H, Carpentier P, Depreux P, Vennin P, Caty A, Sulman C.
    J Nucl Med; 2000 Oct 01; 41(10):1689-94. PubMed ID: 11037999
    [Abstract] [Full Text] [Related]

  • 15. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
    de Klerk JM, van Dieren EB, van het Schip AD, Hoekstra A, Zonnenberg BA, van Dijk A, Rutgers DH, Blijham GH, van Rijk PP.
    J Nucl Med; 1996 Jan 01; 37(1):38-41. PubMed ID: 8543998
    [Abstract] [Full Text] [Related]

  • 16. [Pain therapy in multiple bone metastases in breast carcinoma with rhenium 186 HEDP].
    Hauswirth AE, Palmedo H, Dierke-Dzierzon C, Biersack HJ, Krebs D.
    Zentralbl Gynakol; 1998 Jan 01; 120(2):83-6. PubMed ID: 9531713
    [Abstract] [Full Text] [Related]

  • 17. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
    de Klerk JM, van het Schip AD, Zonnenberg BA, van Dijk A, Quirijnen JM, Blijham GH, van Rijk PP.
    J Nucl Med; 1996 Feb 01; 37(2):244-9. PubMed ID: 8667053
    [Abstract] [Full Text] [Related]

  • 18. Dosage and response in radiopharmaceutical therapy of painful osseous metastases.
    Silberstein EB.
    J Nucl Med; 1996 Feb 01; 37(2):249-52. PubMed ID: 8667054
    [No Abstract] [Full Text] [Related]

  • 19. Rhenium-186 HEDP: palliative radionuclide therapy of painful bone metastases. Preliminary results.
    Schoeneich G, Palmedo H, Dierke-Dzierzon C, Müller SC, Biersack HJ.
    Scand J Urol Nephrol; 1997 Oct 01; 31(5):445-8. PubMed ID: 9406304
    [Abstract] [Full Text] [Related]

  • 20. Rhenium-188-HEDP in the palliative treatment of bone metastases.
    Liepe K, Hliscs R, Kropp J, Grüning T, Runge R, Koch R, Knapp FF, Franke WG.
    Cancer Biother Radiopharm; 2000 Jun 01; 15(3):261-5. PubMed ID: 10941533
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.